Tumor necrosis factor-alpha induction by reovirus serotype 3

J Leukoc Biol. 1993 Feb;53(2):133-7. doi: 10.1002/jlb.53.2.133.


We have reported previously that reovirus, when used in combination with 1,3-bis(chloroethyl)-1-nitrosourea (BCNU) chemotherapy, mediates the rejection of murine ascites tumors. Surviving animals reject a challenge with the same, but not a different, tumor, which suggests that tumor-specific immunity is induced by the treatment regimen. The present study was designed to characterize the interaction between reovirus and murine peritoneal macrophages, both in vitro and in vivo, to determine whether such a relationship may play a role in immune modulation resulting in tumor rejection. The results demonstrated that reovirus can efficiently infect peritoneal macrophages in vitro and stimulate the secretion of tumor necrosis factor-alpha (TNF-alpha). In vivo administration of reovirus, however, did not produce high levels of infection in peritoneal exudate cells, even though the cells were stimulated to express detectable levels of membrane TNF-alpha. These results suggested that infection is not necessary for TNF-alpha expression and this hypothesis was supported by the observation that this expression was also stimulated in vitro by UV-inactivated reovirus. These findings suggest that one mechanism for immune stimulation by reovirus may be through the induction of TNF-alpha.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analysis of Variance
  • Animals
  • Antibodies
  • Cell Transformation, Viral*
  • Cells, Cultured
  • Female
  • Macrophages / drug effects
  • Macrophages / physiology*
  • Mammalian orthoreovirus 3 / genetics
  • Mammalian orthoreovirus 3 / physiology*
  • Mammalian orthoreovirus 3 / radiation effects
  • Mice
  • Mice, Inbred Strains
  • Neutralization Tests
  • Reoviridae Infections / physiopathology*
  • Tumor Necrosis Factor-alpha / biosynthesis*
  • Ultraviolet Rays


  • Antibodies
  • Tumor Necrosis Factor-alpha